Literature DB >> 22134906

It's all in the timing.

Linda J Bendall1.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22134906     DOI： 10.1182/blood-2011-09-381111

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  Tubulin-targeting agent combination therapies: dosing schedule could matter.

Authors:  Eric Solary
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

2.  Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies.

Authors:  H Ehrhardt; L Pannert; S Pfeiffer; F Wachter; E Amtmann; I Jeremias
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

3.  Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.

Authors:  Ondrej Havranek; Petra Kleiblova; Jan Hojny; Filip Lhota; Pavel Soucek; Marek Trneny; Zdenek Kleibl
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

4.  STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models.

Authors:  Gabriela Rozic; Lena Paukov; Ziv Cohen; Irit Shapira; Adrian Duek; Ohad Bejamini; Abraham Avigdor; Arnon Nagler; Igor Koman; Merav Leiba
Journal:  Oncotarget       Date:  2018-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.